Cases & Deals

  • Home
  • Practices
  • Celgene wins in district court case, invalidating patent asserted against its Thalomid® and Revlimid® brand cancer drugs

Share

Celgene wins in district court case, invalidating patent asserted against its Thalomid® and Revlimid® brand cancer drugs

July 2015

Client(s) Celgene Corporation

Jones Day successfully defended Celgene Corporation in a patent infringement case brought in the United States District Court for the District of Delaware by Andrulis Pharmaceuticals Corporation, which alleged that Celgene's THALOMID® and REVLIMID® brand cancer drugs infringed U.S. Patent No. 6,140,346 ("'346 patent"). After Jones Day obtained a ruling that the asserted '346 patent claim is indefinite, the plaintiff agreed that the asserted claim is invalid and stipulated to the entry of a final judgment of invalidity.

Andrulis Pharmaceuticals Corp. v. Celgene Corp., 1:13-cv-01644 (D. Del.)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.